|Funder||Call||Brief Outline||Max value||Outline/ full||Deadline||Link|
|NC3Rs||Project grants||A project grant is a research project which supports the development of new 3Rs approaches and technologies. Applications from any area of medical, biological or veterinary research are within remit; those that integrate a range of disciplines or include an industrial partner are particularly encouraged. Awards are for up to 36 months with the amount requested dependent on the science.||Not specified||Two stage||11/01/17||https://www.nc3rs.org.uk/funding/project-grants?utm_source=newsletter&utm_campaign=December%202016&utm_medium=email|
Novel Analytical Approaches for Metabolomics Data (R03)
|The purpose of this small research grant Funding Opportunity Announcement (FOA) is to foster collaboration between computational scientists, metabolomics experts, and biomedical researchers in developing, piloting, and/or validating novel bioinformatic approaches that address current analytical hurdles in metabolomics data. A goal of providing powerful approaches that will be useful to biomedical researchers, as well as bioinformaticians, is particularly encouraged. Projects are not intended to supplement ongoing metabolomics analyses, but to provide a tool for broader use by the biomedical research community. Projects are expected to use existing, publicly available metabolomics data and complement the efforts and resources of the Common Fund Metabolomics Program.||$100,000||Two stage||14/01/17||https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-17-001.html|
|European Society for Paediatric Endocrinology, GB||Congenital adrenal hyperplasia grant||This supports research on congenital adrenal hyperplasia and aims to improve understanding of pathophysiology of the disease and its management. Specific goals include:
•increasing knowledge on pathophysiology of the disease;
•prevention, diagnostic and treatment of natural or iatrogenic complications;
•proposition of new therapeutic targets and protocols.
Applicants must hold an MD, PhD, or equivalent academic degree and have a faculty position or equivalent at a college, university, medical school, or comparable institution. Only one project per research team will be considered. Participation is mostly restricted to Europeans teams, however teams working from all over the world may apply if at least one of the PIs involved in the project belongs to a European team. Teams from anywhere in the world who are working on projects aimed at gene or cellular therapies approaches in CAH may apply without a European PI.
The total budget is €350,000. Grants are worth up to €150,000 each over three years, to cover expenses directly linked to the project, including specific equipment, operating costs or salaries of co-workers.
|€ 150,000||Two stage||16/01/17||http://www.eurospe.org/science/ifcah.html|
|Dunhill Medical Trust||Research grants||The Dunhill Medical Trust invites applications for its research grants. These encourage and support research with a focus on improving the health and wellbeing of older people. The following areas are of particular interest:
•care of older people, including rehabilitation and palliative care;
•research into the causes and treatments of disease, disability and frailty related to ageing.
Priority will be given to clinical and applied research, health services research, public health research and research carried out on a multidisciplinary basis as well as activities that will expand research capacities in these areas.
Grants are normally made directly to researchers within academic or NHS institutions; the lead applicant should be the principal investigator.
Research project grants are normally within the range of £25,000 to £300,000 each for a period up to three years and research programme grants within the range of £300,000 to £1 million each for a period up to five years.
|RCUK||Non-GLP dose range finding and cardiovascular safety studies||Research Councils UK, via the UK Shared Business Services, invites tenders for non-GLP dose range finding and cardiovascular safety studies. The tenderer will conduct non-GLP dose range finding and cardiovascular safety studies for a single compound in rat as a prelude to conducting the pre-clinical toxicity testing, required by regulators prior to administering the compound to humans.
The contract is worth between £80,000 and 90,000, and will start on 7 February and end on 30 April 2017.
Ref: UK SBS RE160428.
|World Federation of Hemophilia, CA||Clinical research grant programme||The World Federation of Hemophilia invites applications for its clinical research grants. These support international clinical investigation relating to inherited bleeding disorders. The programme aims to help create better evidence for the clinical management of haemophilia A and B, von Willebrand disease, rare factor deficiencies and inherited platelet disorders.
Applicants affiliated with a recognised medical, scientific, or academic institution, haemophilia or inherited bleeding disorder treatment centre or WFH national member organisation or its affiliated chapters are eligible to apply. PhD students are not eligible and the principal applicant must hold a faculty position at a recognised medical, scientific or academic institution. There are no restrictions on applicant’s nationality.
Up to four grants, worth up to CAD 50,000 per year each, are available for a maximum period of two years.
|Fight for Sight||Chief Scientist Office project grants||These support a Scottish-led biomedical research project into age-related eye disease such as glaucoma, age-related macular degeneration and cataract. Research must address one of the following priority areas:
•developing ways of preventing eye diseases;
•developing new and improved treatments for eye diseases and conditions;
•increasing understanding of how eye diseases and conditions start and develop;
•enabling eye diseases to be detected earlier.
Applicants must have a tenured post at a recognised Scottish university, NHS hospital or research institute and must have a contract which extends beyond the termination date of the fellowship. Research should be of clinical importance to the Scottish population and broadly translational.
Grants are worth up to £200,000 over three years. Funding covers salary, consumables and equipment.
|MS Society||Daphne Jackson Fellowship||Applications are invited for a Daphne Jackson Fellowship that will be half sponsored by the MS Society. The fellowship is intended for individuals returning to research following a career break of two or more years. The fellowship can be held in any UK academic institution. The remaining funding will be secured by the Daphne Jackson Trust from an additional sponsor.
The MS Society supports research to improve the quality of life of people affected by MS and to develop better interventions to prevent and treat MS.
|British HIV Association||Research Awards||These support research projects that impact on the improvement of clinical care and management of people living with HIV in the UK, including projects that focus on finding a cure.
Projects should fall within one of the following categories:
•access and service delivery;
•age, gender and migration related issues;
•transitional research, immunology and virology;
•HIV-related cancer and malignancies;
•children and pregnancy;
•complications of HIV disease or treatment;
•diagnosis and testing;
•epidemiology and surveillance;
•HIV treatment and pharmacokinetics;
•clinical management issues in HIV;
•opportunistic and co-infections;
•pathogenesis and prevention;
•sexually transmitted infections.
Members of the association who are clinical or non-clinical researchers may apply. Preference is given to applicants who are not yet independent researchers or who do not hold an established academic or clinical post.
The minimum budget in 2017 is £70,981.89. Awards are worth up to £10,000 in some categories, and up to £30,000 in other categories.
|North American Spine Society, US||Research Grants||The North American Spine Society invites applications for its research grants. These support research projects in the field of spine.
Applicants may be from any field and of any nationality.
New investigators are encouraged to apply. Medical residents may be considered provided that they have a mentor or faculty support.
Grants are generally worth up to USD 50,000 per year over a period of one to two years. Cost-sharing is encouraged. Projects must be completed within three years.
|Wellbeing of Women||Research grants||These support projects in basic science, clinical or translational research in the areas of pregnancy and childbirth, including pre-term birth, miscarriage and fertility, quality of life issues such as menopause, incontinence and prolapse, sexual health, menstrual disorders and endometriosis, and gynaecological cancers. Applications with the potential to make translational impact in the following areas are encouraged:
Applicants from around the UK and Republic of Ireland may apply. Research must be undertaken in these countries.
Grants are worth up to £200,000 over one to three years.
|Cancer Research UK||Science Committee Programme Awards||Cancer Research UK invites applications for its science committee programme grants. These provide long-term support for broad, multidisciplinary research where the aim is to answer questions spanning basic and translational research. Research proposals should address the following areas:
•basic biological research relating to cancer;
•preclinical studies that will generate biological data to underpin therapeutic development;
•the application of engineering and physical sciences to cancer.
Scientists, clinicians or healthcare workers in UK universities, medical schools, hospitals and some research institutions may apply.
Awards are worth up to £2.5 million each for up to five years. Funding may be used for salaries for researchers and technical staff, and the stipend, fees and running expenses of PhD students, running expenses and equipment.
|Action on Hearing Loss||International Project Grant||This aims to generate scientific discoveries that will lead to new treatments to protect, improve or restore hearing, or to silence tinnitus. Research projects should focus on the following areas:
•improving diagnosis of hearing loss;
•improving medical devices for hearing;
•understanding and prevention of hearing disorders;
•restoration of hearing;
Projects that address areas of tinnitus and Méniere’s disease are encouraged.
Applicants may be from any university or research institute based anywhere in the world. Lead applicants may submit only one application, but may be named as a co-applicant or collaborator on other applications.
The grant is worth up to £55,000 per year for up to three years. The total budget is £160,000.
|Arthritis Research UK||Transforming musculoskeletal health challenge||Funding supports research that focuses on improvements in the quality of life of people with arthritis, or contributes to the evidence base of knowledge that will lead to improvements relevant to people with arthritis and musculoskeletal conditions.
Any academic, clinician or allied healthcare professional based at an eligible UK institution may apply. Applicants based at businesses are not eligible, but may participate as co-applicants. All applications must have a lead applicant or another co-applicant that is tenured.
Awards are worth up to £400,000 each over a maximum period of four years. Larger funding amounts may be granted, but require prior agreement from ARUK. Funding covers running and equipment costs.
|EU Joint Programme for Neurodegenerative Disease Research, EU and other funders||Multinational research projects for pathway analysis across neurodegenerative diseases||The EU Joint Programme for Neurodegenerative Disease invites proposals for its joint transnational call on multinational research projects for pathway analysis across neurodegenerative diseases. This supports multidisciplinary research that performs network analyses across different neurodegenerative and other chronic diseases and elucidates the underlying mechanisms involved. Research proposals may:
•combine experimental approaches from fundamental, pre-clinical or clinical research;
•perform network analyses in different neurodegenerative or other chronic diseases to elucidate the underlying common and differing mechanisms in the investigated diseases;
•add value to existing research by analysing diseases across traditional clinical boundaries, technologies and disciplines, thereby gaining deeper understanding of the patho-physiological mechanisms of neurodegenerative diseases.
The call includes Alzheimer’s disease and other dementias, Parkinson’s disease and PD‐related disorders, Prion diseases, motor neuron diseases, Huntington’s disease, spinocerebellar ataxia and spinal muscular atrophy. Cross-disease analysis may solely comprise different neurodegenerative diseases or include other chronic diseases.
Up to six research groups from at least three different countries may collaborate within a consortium.
|Not specified||Two stage||06/03/17||http://www.neurodegenerationresearch.eu/2016/11/joint-transnational-call-for-research-proposals-pre-announcement/|
|Action on Hearing Loss||Pauline Ashley new investigator grant scheme||This aims to build research capacity in hearing research by supporting the career development of the UK’s most talented new investigators towards becoming independent scientists. Applications are invited in any of the following areas;
•diagnosis of hearing loss and tinnitus, including genetics and early detection of deafness;
•improved benefit from medical devices, such as hearing aids and cochlear implants;
•treatments to protect or restore hearing, investigation of the mechanisms underlying hearing loss and the development of therapies to prevent hearing loss;
Applicants should be early career investigators who hold a PhD and are based at a university or research institute in the UK, but are not permanent employees.
The award is worth up to £60,000 for a duration of one year.
|Consumers, Health, Agriculture and Food Executive Agency, EU||PJ-06-2016 rare disease registries||This supports the creation of new registries on rare diseases which should constitute key instruments to increase knowledge on rare diseases and develop clinical research.
Collaborative efforts to establish data collection and maintain them will be considered, provided that these resources are open and accessible. Registries should be built with the support and according to the standards set up by the European platform on rare diseases registration, and they should provide all necessary data to the platform.
Proposals are accepted from applicant organisations that are members of approved European Reference Networks. Projects must involve at least three partners from separate legal entities and from different countries. Applicant organisations must be based in EU member states, Iceland, Norway or Serbia, and may include public authorities, public sector bodies, research and health institutions, universities and higher education establishments.
The total budget is €1.2 million. Between three to four registries are expected to be funded at a maximum of €400,000 per project. Projects may last up to 36 months.
|Innovative Medicines Initiative Joint Undertaking, EU||H2020-JTI-IMI2-2016-10 IMI tenth call for proposals – two stage||The Innovative Medicines Initiative Joint Undertaking invites proposals for its tenth call. This aims to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need. Proposals may address the following topics:
•IMI2-2016-10-01 understanding hypoglycaemia – the underlying mechanisms and addressing clinical determinants as well as consequences for people with diabetes by combining databases from clinical trials, worth up to €26.92 million over 48 months;
•IMI2-2016-10-02 how big data could support better diagnosis and treatment outcomes for prostate cancer, worth up to €12m over 60 months;
•IMI2-2016-10-03 improving the care of patients suffering from acute or chronic pain, worth up to €22.46m over 39 months;
•IMI2-2016-10-04 creation of a pan-European paediatric clinical trials network, worth up to €134m over 72 months;
•IMI2-2016-10-05 biomanufacturing 2020: development of innovative high throughput analytical tools and methods to characterise cell culture fluid during development and commercial cell culture processes, worth up to €9.4m over 48 months;
•IMI2-2016-10-06 unlocking the solute carrier gene-family for effective new therapies, worth up to €24m over 60 months;
•IMI2-2016-10-07 enhanced patient voice in medicines life cycle, worth up to €8.75m over 30 months;
•IMI2-2016-10-08 personalised medicine approaches in autism spectrum disorders, worth up to €110.5m over 60 months.
Proposals must take the form of research and innovation actions, requiring participation by at least three legal entities, each established in a different EU member state or associated country. Micro to medium-sized companies with an annual turnover of €500 million or less, secondary and higher research establishments and non-profit organisations, established in an EU member state or an associated country are eligible.
The total budget for the call is worth €348.03m.
|See text||Two stage||28/03/17||http://ec.europa.eu/research/participants/portal/desktop/en/opportunities/h2020/calls/h2020-jti-imi2-2016-10-two-stage.html#c,topics=callIdentifier/t/H2020-JTI-IMI2-2016-10-two-stage/1/1/1/default-group&callStatus/t/Forthcoming/1/1/0/default-group&callStatus/t/Open/1/1/0/default-group&callStatus/t/Closed/1/1/0/default-group&+identifier/desc|
|Action Medical Research for Children||Joint Borne Awards||These support translational research projects to prevent death and disability in babies and children as a result of pregnancy complications. Eligible projects include pilot studies that will generate data enabling larger scale applications to funding bodies or practical application. Research may be in the following fields:
•preterm birth and factors leading to preterm birth;
•intrauterine growth restriction;
•maternal environment to ensure healthy babies;
•development of the baby during pregnancy;
•monitoring fetal health during pregnancy;
•monitoring the health of the baby during delivery;
•preparation for pregnancy to improve outcomes for the baby including nutrition;
•studies that follow the outcomes of babies and children following treatments given during pregnancy;
•neonatal care including necrotising enterocolitis;
•neonatal and perinatal interventions to reduce the long term consequences of birth asphyxia.
The principal investigator must be employed in a permanent position in a UK university or institution. Fixed term employees on a long term contract may be eligible providing the term of employment extends at least six months beyond the duration of the proposed research project. Research workers who have made a substantial intellectual contribution to the grant proposal may be named as co-applicants with an established member of staff as the principal applicant.
The total budget is £500,000. Grants are worth up to £200,000 each over three years, or up to £75,000 each over 18 months for pump-priming awards.
|ARSEP Foundation||Research grants||ARSEP Foundation welcomes any basic and clinical research applications focused on Multiple Sclerosis, including for example: immunologic basis of MS, myelin biology, axonal degeneration, restoration of myelin and axonal integrity, susceptibility to MS, virology, infectious disease processes that may trigger disease activity, imaging technology, identification and use of surrogate markers, clinical research and therapeutics, and so on. Regulations about research grants:
##Research projects taking place outside of France can be funded by Foundation ARSEP provided they are integrated into a multicenter project including at least one French team with a major role in the project.
##A principal investigator (PI) can only submit one project.
##Funding will be granted for one year, renewable after resubmission.
##Funding is for laboratory expenses, equipment, access to a technology platform... Funding for a technician can be requested, but the amount for the salary cannot exceed 1/3 of the total requested amount.
##A fixed amount will be awarded: 50 000 € maximum per project.
|Arthritis Research UK||Career development fellowship||This enables a postdoctoral scientist or an allied health professional to develop their career with an established sponsor, preferably within a multidisciplinary research group in a UK university department, hospital or research institute.
The application should be made jointly by the candidate and their sponsor. Each candidate should normally have at least three years of postdoctoral research experience. Medically or surgically qualified individuals are ineligible.
|Arthritis Research UK||Foundation Fellowship||Arthritis Research UK invites applications for its foundation fellowship. This aims to retain the best postdoctoral researcher in research areas relevant to arthritis and musculoskeletal disease, and provide an opportunity for the fellow to develop independent research ideas at an early stage in their career. Applications related to ARUK’s strategic focus on improving the quality of life of people with arthritis are encouraged.
Applicants should be basic science or non-medical PhD students who are in the final year of training or within one year of completing their PhD. Preference is given to applicants who wish to move to another laboratory in the UK or, if remaining in the same institution, spend a period of time in another laboratory. The application should be made jointly by the applicant and their sponsor, who should not be the applicant’s previous PhD supervisor.
The fellowship is normally awarded for three years and covers salary, reasonable running costs and purchase of small items of equipment up to £30,000.
|Wellcome Trust||Collaborative Awards in Science|| *** The Wellcome Trust has brought forward the closing date for its collaborative awards in science. The previous deadline of 23 May 2016 has now been brought forward to 26 April 2016. All other call information remains unchanged. These support groups of independent researchers pursuing problems across the areas of science, medical humanities, society and ethics, and innovation. Awards are normally worth up to £4 million over a period of up to five years. ***These support groups of independent researchers pursuing problems across the areas of science, humanities and social science and innovation.
Teams should normally consist of no more than seven applicants. Interdisciplinary research collaborations between basic scientists or medical and veterinary clinicians, and non-biologists, such as mathematicians, physicists, chemists, engineers and social scientists, are encouraged.
Awards are normally worth up to £4 million over a period of up to five years. Funding may be used to cover research expenses, travel and subsistence, overseas allowances, research management and support costs. A provision for public engagement costs may also be awarded.
|MRC||Career development award||This award enables postdoctoral researchers to lead their own research plans and establish their own research team to make the transition from postdoctoral researcher to independent investigator. Proposals are encouraged across all areas of the research council’s remit, and they may range from basic studies with relevance to mechanisms of disease, to translational and developmental clinical research.
Applicants are normally expected to have a PhD; however, in some cases applicants without a PhD may be considered. Applicants who hold a tenured academic position are not eligible. There are no eligibility rules based on postdoctoral experience. Applicants must be able to demonstrate that their skills and experience match those of the transition to independence career stage.
Funding provides salary, support for research staff, consumables, travel costs and capital equipment appropriate for the research project. The maximum duration of an award is five years. There is no limit for funding.
MRC encourages applicants to consider the funding for research outside the UK, at a second UK institution or within industry in order to establish collaborative networks or cross-sector development.
|Salary and expenses||Full||25/04/17||http://www.mrc.ac.uk/skills-careers/fellowships/non-clinical-fellowships/career-development-award-cda-transition-to-independence/|
|Parkinson's UK||Career development award fellowships||Parkinson's UK, in collaboration with the Medical Research Council, under the career development award scheme invites applications for its career development award fellowships. These are for postdoctoral researchers to lead their own research plans and establish their own research team to make the transition from postdoctoral researcher to independent investigator in research relevant to Parkinson's.
The fellow must plan to be based at the lead organisation at which the award will be administered and all applicants are expected to demonstrate a commitment to strengthening the UK research base beyond the period of their fellowship. The lead organisation is responsible for administering the grant and must be a HEI, independent research organisation, or a MRC unit or institute. As part of a jointly funded award, fellows will be required to submit annual and final reports to Parkinson’s UK and will also be asked to host up to two engagement activities with people affected by Parkinson's.
Fellowships are worth approximately £1 million each over a five year period. It is likely that one fellowship will be awarded.
|MRC||New investigator research grant – molecular and cellular medicine||This supports researchers who are capable of becoming independent principal investigators and who are ready to take the next step towards that goal within the areas of molecular and cellular medicine. Applicants are expected to combine their time with a portfolio of other activities, such as other research grants or clinical duties, teaching, administration duties, or other time spent in faculty.
Applicants should hold a PhD or a medical degree and they may hold a lecturer appointment, a junior fellowship or be in a research staff position. In addition, those who hold or have held early-career training fellowships may apply. Co-investigators are welcomed too.
Applicants may request support for the following:
•a salary commensurate with the time attributed to the project, which is capped at 50 per cent of the applicant’s total contracted working time;
•a salary for the hours attributable to the project of any co-investigators;
•support for additional research or technical costs;
•consumables and equipment;
•data preservation, data sharing and dissemination costs.
Grants are tenable for three years and are usually given on the basis of 80 per cent of full economic costs of the research to the applicant’s institution.
|MRC||Programme grant – molecular and cellular medicine||These provide large and long-term renewable funding for a coordinated and coherent group of related projects that may be developed to address an interrelated set of questions across a broad scientific area. The expectation is that not all questions will necessarily be answered within the tenure of the award. Parts of the programme may be continuations of current activity, but other elements should be innovative and ambitious.
Any UK-based researcher who can demonstrate that they will direct the proposed research and be actively engaged in carrying it through may apply. The minimum academic qualification required is a graduate degree, although a PhD is usually expected. The PI should have a substantial record of successfully securing research funding and delivering high quality research. MRC units and university units are not eligible to apply.
Grants can last for a maximum period of five years and can include:
•a portion of the salaries of the principal investigator and co-investigators;
•additional research and technical posts;
•data preservation, data sharing and dissemination costs.
The MRC will fund on the basis of 80 per cent of full economic costs of the research to the applicant’s institution.
|MRC||Research grant – molecular and cellular medicine||These are intended for focused research projects that may be short- or long-term in nature. In addition, they can be used to support method development and continuation of research facilities and may involve more than one research group or institution.
Any UK-based researcher who can demonstrate that they will direct the proposed research and be actively engaged in carrying it through may apply. The minimum academic qualification required is a graduate degree, although usually a PhD is required. Less experienced researchers should apply in collaboration with a more senior colleague. Applications may include industry partners.
Grants do not typically exceed £1 million. Funding is usually given on the basis of 80 per cent of full economic costs of the research to the applicant’s institution. Grants can be awarded for any period of up to five years, but those of two years or less are for proof of principle or pilot work only.
|European Society for Medical Oncology, CH||Translational research fellowships||These support research in oncology through training, career development and translational research projects.
Applicant must be:
•ESMO members, 40 years of age or under;
•oncologists with at least one year of experience in medical, radiation or surgical oncology and be currently engaged in cancer research or clinical oncology practice;
•proficient in English.
Fellowships are worth €40,000 for one year, with the possibility of an additional €40,000 for a second year. Host institutes receive €1,000 towards administrative costs.
|National Institute of Mental Health (NIMH)National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Neurological Disorders and Stroke (NINDS)
|Eradication of HIV-1 from Central Nervous system Reservoirs (R01)||This Funding Opportunity Announcement (FOA) invites research grant applications studying mechanisms of HIV-1 persistence and eradication strategies specifically focused on the central nervous system (CNS) in the context of viral suppression. Basic and translational research in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged but not required.||Not limited||Full||07/05/17||https://grants.nih.gov/grants/guide/pa-files/PA-17-084.html|
|Cancer Research UK||Cancer Immunology Project Awards||The Cancer Immunology Awards should address key questions in the immunology of cancer. Applications can be in any area of immunological research, providing the cancer relevance is clearly articulated in the proposal, including any of the following key areas:
•Cellular and molecular immunology, including but not limited to mechanisms of tolerance; the regulation of immune function, and; the development of memory
•Inflammation, allergy, transplantation and auto immunity (how the basic understanding of relevant mechanisms involved could drive forward our understanding of cancer)
•The immune response to infection
•The interaction of immune cells with tissues
•Immunity and disease susceptibility/resistance
This award does not support the development of new biotherapeutics or immunomodulatory agents.
|National Institute of Mental Health (NIMH)||Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01)||
This Funding Opportunity Announcement (FOA) seeks to support clinical trials to establish the effectiveness of interventions and to test hypotheses regarding moderators, mediators, and mechanisms of action of these interventions. This FOA supports clinical trials designed to test the therapeutic value of treatment and preventive interventions for which there is already evidence of efficacy, for use in community and practice settings. Applications might include research to evaluate the effectiveness or increase the clinical impact of pharmacologic, somatic, psychosocial (psychotherapeutic, behavioral), device-based, rehabilitative and combination interventions to prevent or treat mental illness. This FOA also supports clinical trials to test patient-, provider-, organizational-, or systems-level services interventions to improve access, continuity, quality, equity, and/or value of services. The intervention research covered under this announcement is explicitly focused on practice-relevant questions.
This FOA should be used when two or more sites are needed to complete the study. Accordingly, the collaborating studies share a specific protocol across the sites and are organized as such in order to increase sample size, accelerate recruitment, or increase sample diversity and representation. Each site has its own Program Director/Principal Investigator (PD/PI) and the program provides a mechanism for cross-site coordination, quality control, database management, statistical analysis, and reporting. This FOA should be used for applications preparing to complete the study. Support for fully-powered effectiveness studies via a single R01 grant is provided through a separate FOA, RFA-MH-17-608 "Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Applications (R01)."
|Not limited||Two stage||14/05/17||https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-17-610.html|
|National Institute of Mental Health (NIMH)||Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01)||This Funding Opportunity Announcement (FOA) seeks to support clinical trials to establish the effectiveness of interventions and to test hypotheses regarding moderators, mediators, and mechanisms of action of these interventions. This FOA supports clinical trials designed to test the therapeutic value of treatment and preventive interventions for which there is already evidence of efficacy, for use in community and practice settings. Applications might include research to evaluate the effectiveness or increase the clinical impact of pharmacologic, somatic, psychosocial (psychotherapeutic, behavioral), device-based, rehabilitative and combination interventions to prevent or treat mental illness. This FOA also supports clinical trials to test patient-, provider-, organizational-, or systems-level services interventions to improve access, continuity, quality, equity, and/or value of services. The intervention research covered under this announcement is explicitly focused on practice-relevant questions. Applicants interested in submitting multi-site effectiveness trials (e.g., to answer primary effectiveness questions and key questions regarding moderators/mechanisms, to ensure geographic and demographic diversity)are directed to RFA-MH-17-610 "Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01)".||Not limited||Two stage||14/05/17||https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-17-608.html|
|National Institute of Mental Health (NIMH)||Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01)||The purpose of this Funding Opportunity Announcement (FOA) is to support confirmatory efficacy testing of non-pharmacological therapeutic and preventive interventions for mental disorders in adults and children through an experimental therapeutics approach. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support "go/no-go" decisions about further development, effectiveness testing, or dissemination of the intervention. Interventions to be studied include, but are not limited to behavioral, cognitive, interpersonal, and device-based (both invasive/surgically implanted as well as noninvasive/transcranial) approaches, or a combination thereof. Interventions appropriate for efficacy testing must be based on a compelling scientific rationale, previous demonstration that the intervention engages and alters the hypothesized mechanism of action, a preliminary efficacy signal, and must address an unmet therapeutic need. Support will be provided for a trial of the intervention's efficacy that includes measurement of the hypothesized mechanism of action and the relationship between change in the mechanism and change in functional or clinical effects. Ultimately, this FOA is intended to support a sufficiently-powered efficacy trial to determine the intervention's potential for significant clinical benefit.||Not limited||Two stage||14/05/17||https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-17-614.html|
|National Institute of Mental Health (NIMH)||Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33)||The purpose of this Funding Opportunity Announcement (FOA) is to support the efficient pilot testing of novel psychosocial therapeutic and preventive interventions for mental disorders in adults and children, using an experimental therapeutics approach. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support ”go/no-go” decisions about further development or testing of the intervention. This FOA supports the development and testing of innovative psychosocial intervention approaches where the target and/or the intervention strategy are novel. Targets might include, but are not limited to, potentially modifiable behavioral, cognitive, affective and/or interpersonal factors or processes, neural circuits or neural activity subserving specific behaviors or cognitive processes, and/or other neurobiological mechanisms associated with risk for, causation of, or maintenance of a mental disorder. Eligible psychosocial intervention strategies might include in-person or technology-assisted delivery, provided the target and/or the intervention strategy is novel. This FOA supports the development and testing of novel psychosocial interventions, as defined above, as monotherapies or as augmentations to standard treatment. Support will be provided for up to 3 years for studies to replicate previous target engagement findings, and relate change in the intervention target/mechanism to clinical benefit. Ultimately, this FOA is intended to speed the translation of emerging basic science findings of mechanisms and processes underlying mental disorders into novel interventions that can be efficiently tested for their promise in restoring function and reducing symptoms for those living with mental disorders, or for preventing mental disorders among those at risk.||Not limited||Two stage||14/05/17||https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-17-606.html|
|National Institute of Mental Health (NIMH)||Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33)||The purpose of this Funding Opportunity Announcement (FOA) is to support the efficient pilot testing of novel psychosocial therapeutic and preventive interventions for mental disorders in adults and children, using an experimental therapeutics approach. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support ”go/no-go” decisions about further development or testing of the intervention. This FOA supports the development and testing of innovative psychosocial intervention approaches where the target and/or the intervention strategy is novel. Targets might include, but are not limited to, potentially modifiable behavioral, cognitive, affective and/or interpersonal factors or processes, neural circuits or neural activity subserving specific behaviors or cognitive processes, and/or other neurobiological mechanisms associated with risk for, causation of, or maintenance of a mental disorder. Eligible psychosocial interventions strategies might include in-person or technology-assisted delivery, provided the target and/or the intervention strategy is novel. This FOA supports the development and testing of novel psychosocial interventions, as defined above, as monotherapies or as augmentations to standard treatment. Support will be provided for up to two years (R61 phase) for preliminary milestone-driven testing of the intervention’s impact on a target (a process or mechanism associated with risk for, causation, or maintenance of a clinical condition), that is, its target engagement. Contingent on meeting “go/no-go” milestones in the R61 phase, up to 3 years of additional support (R33 phase) may be provided for studies to replicate target engagement and relate change in the intervention target/mechanism to clinical benefit. Ultimately, this R61/R33 FOA is intended to speed the translation of emerging basic science findings of mechanisms and processes underlying mental disorders into novel interventions that can be efficiently tested for their promise in restoring function and reducing symptoms for those living with mental disorders, or for preventing mental disorders among those at risk.||Not limited||Two stage||14/05/17||https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-17-604.html|
|National Institute of Mental Health (NIMH)||Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34)||The purpose of this Funding Opportunity Announcement (FOA) is to encourage pilot research consistent with NIMH's priorities for: 1) effectiveness research on preventive and therapeutic interventions with previously demonstrated efficacy, for use with broader target populations or for use in community practice settings, and 2) research on the development and preliminary testing of innovative services interventions. Applications should provide resources for evaluating the feasibility, tolerability, acceptability and safety of approaches to improve mental health/functional outcomes, to modify risk factors, or to improve service delivery, and for obtaining the preliminary data needed as a pre-requisite to a larger-scale intervention trial (e.g., comparative effectiveness study, practical trial) or large-scale services study.
In this pilot phase of effectiveness research, NIMH places highest priority on approaches that can be justified in terms of their potential to substantially impact practice and public health and approaches that are empirically grounded. Adaptations or augmentations of efficacious interventions should only be undertaken if there is an empirical rationale for the adaptation target and for the corresponding mechanism by which the adapted intervention or augmentation is expected to substantially enhance outcomes. This FOA is intended to support pilot effectiveness trials that are designed to explicitly address whether the intervention engages the target(s)/mechanism(s) presumed to underlie the intervention effects.
|National Institute of Mental Health (NIMH)||Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33)||The purpose of this Funding Opportunity Announcement (FOA) is to support the early stage testing of pharmacologic interventions with novel mechanisms of action or device-based interventions, for the treatment of symptoms or domains of altered functions in individuals with mental illness (e.g. schizophrenia, depression, autism, obsessive compulsive disorder, anxiety, bipolar disorder, etc.). Early intervention studies are also encouraged where symptoms of a disorder have been identified in subjects (a prodromal phase), prior to full diagnosti|